NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Philip Morris International Inc. (NYSE:PM) concerning possible violations of federal securities laws and/or breaches of fiduciary duty by the Board of Directors.
A Reuters report published on December 20, 2017 stated that “[f]ormer employees and contractors [of Phillip Morris] have detailed irregularities in the clinical experiments that underpin Philip Morris International’s application to the FDA for approval of its iQOS smoking device.” The report went on the state, “Tamara Koval, who worked at the company from 2012 to 2014 and helped coordinate clinical trials for the device, questioned the quality of some of the researchers and sites contracted to carry out those experiments,” adding that, “after [Koval] raised concerns about the Polish study with Philip Morris executives in Switzerland she was excluded from meetings.”
Following this report, shares of Philip Morris fell during intraday trading on December 20, 2017. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.